Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a clinical-stage biotech company specializing in RNA interference (RNAi) therapeutics. The company is headquartered in Pasadena, California, and was founded in 2009. Arrowhead develops innovative medicines that target the underlying cause of disease by silencing specific genes.

Overview

| Attribute | Details | [@trim2024]
|-----------|---------| [@arrowhead2024]
| Founded | 2009 | [@takeda2017]
| Headquarters | Pasadena, California, USA | [@rnai2023]
| IPO | NASDAQ: ARWR (2014) |
| Market Cap | ~$2.5B (2024) |
| Employees | ~400 |
| Website | arrowheadpharma.com |

Technology Platform

TRiM™ (Targeted RNAi Molecule)

Arrowhead's proprietary TRiM™ platform enables precise delivery of RNAi therapeutics:

• Trigger molecules: Proprietary RNAi constructs
• Targeting ligands: Various tissue-specific ligands for organ targeting
• Structural components: Optimized for stability and efficacy
• Delivery system: Conjugate-based delivery without viral vectors

Key Advantages

Pipeline Focus

Current Focus Areas

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a clinical-stage biotech company specializing in RNA interference (RNAi) therapeutics. The company is headquartered in Pasadena, California, and was founded in 2009. Arrowhead develops innovative medicines that target the underlying cause of disease by silencing specific genes.

Overview

| Attribute | Details | [@trim2024]
|-----------|---------| [@arrowhead2024]
| Founded | 2009 | [@takeda2017]
| Headquarters | Pasadena, California, USA | [@rnai2023]
| IPO | NASDAQ: ARWR (2014) |
| Market Cap | ~$2.5B (2024) |
| Employees | ~400 |
| Website | arrowheadpharma.com |

Technology Platform

TRiM™ (Targeted RNAi Molecule)

Arrowhead's proprietary TRiM™ platform enables precise delivery of RNAi therapeutics:

• Trigger molecules: Proprietary RNAi constructs
• Targeting ligands: Various tissue-specific ligands for organ targeting
• Structural components: Optimized for stability and efficacy
• Delivery system: Conjugate-based delivery without viral vectors

Key Advantages

Pipeline Focus

Current Focus Areas

| Area | Programs | Status |
|------|----------|--------|
| Cardiometabolic | ARO-APOC3, ARO-ANG3 | Phase 2/3 |
| Pulmonary | ARO-RAGE, ARO-MMP7 | Phase 1/2 |
| Oncology | ARO-HIF2a, ARO-LUNG1 | Phase 1/2 |
| Virology | HBV, SARS-CoV-2 | Clinical |

Neurological Disease Applications

CNS Delivery Challenges

Arrowhead is actively working on CNS delivery:

• Lung delivery: Studies show lung exposure enables CNS entry via neural pathways
• TROVAC: Technology for crossing the blood-brain barrier
• Collaboration with University of Utah: CNS-targeted RNAi programs

Potential Neuro Applications

Key Programs

ARO-APOC3

• Target: Apolipoprotein C-III
• Indication: Hypertriglyceridemia, familial chylomicronemia
• Phase: Phase 3
• Partner: Takeda (outside US)

ARO-ANG3

• Target: Angiopoietin-like protein 3
• Indication: Dyslipidemia
• Phase: Phase 2

ARO-HIF2a

• Target: Hypoxia-inducible factor 2-alpha
• Indication: Renal cell carcinoma, solid tumors
• Phase: Phase 1/2

Clinical Progress

| Year | Milestone |
|------|-----------|
| 2014 | IPO on NASDAQ |
| 2019 | First CNS program IND submission |
| 2021 | Positive Phase 2 data for ARO-APOC3 |
| 2023 | FDA Fast Track for ARO-APOC3 |
| 2024 | Multiple Phase 3 trials initiated |

Business Development

Partnerships

| Partner | Focus | Deal Value |
|---------|-------|------------|
| Takeda | Cardiometabolic (APOC3) | $1.1B+ |
| Janssen | RNAi platform | $3.7B |
| Amgen | Cardiovascular | $617M |

Competitive Landscape

| Company | Technology | Strength |
|---------|------------|----------|
| Alnylam Pharmaceuticals | RNAi | First mover, 5 approved drugs |
| Ionis Pharmaceuticals | ASO | Broad pipeline |
| Dicerna | GalNAc-RNAi | Liver targeting |
| Arrowhead | TRiM | Versatile delivery |

NeuroWiki Cross-References

• RNA Interference
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration) RNA Therapeutics
• Companies Index
• [RNAi Therapeutics](/genes/th)
• [Gene Therapy](/therapeutics/gene-therapy)
• [Alzheimer's Disease Pipeline Companies](/diseases/mpan)
• [Parkinson's Disease Pipeline Companies](/genes/ar)
• [Companies Index](/diseases/mpan)

External Links

• [Arrowhead Pharmaceuticals Website](https://arrowheadpharma.com)
• [Arrowhead Pipeline](https://arrowheadpharma.com/pipeline/)

References